Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AGIOS PHARMACEUTICALS, INC. (AGIO)

Agios stockholders approve 2,000,000-share increase to 2023 stock incentive plan

Neutral Impact 2 of 5 shareholder Written later

At its June 18, 2026 annual meeting, Agios stockholders approved an amendment adding 2,000,000 shares to the 2023 Stock Incentive Plan, with the same increase for incentive stock options. Stockholders also re-elected Class I directors Rahul Ballal, Brian Goff and Cynthia Smith, approved the advisory pay vote for named executive officers, and ratified PricewaterhouseCoopers LLP as auditor. The larger share reserve gives the company more shares available for equity awards.

Key points

  • 2,000,000 additional shares added to the 2023 Stock Incentive Plan; 43,549,751 votes for and 2,527,678 against the amendment
  • Class I directors elected for three-year terms expiring at the 2029 annual meeting: Rahul Ballal, Ph.D., Brian Goff and Cynthia Smith
  • Smith received 31,496,376 votes for and 14,592,704 withheld, the lowest support of the three director nominees
  • PricewaterhouseCoopers LLP ratified as independent registered public accounting firm, with 48,511,213 votes for

The filing

CompanyAGIOS PHARMACEUTICALS, INC. (AGIO)
Form8-K, current report
Filed with the SECJun 18, 2026, 4:13 PM ET
Accession number0001193125-26-275879

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.